In 899 adults with untreated high-risk DLBCL or HGBL, adding tafasitamab and lenalidomide to R-CHOP improved progression-free survival vs R-CHOP plus placebo (HR 0·75; 2-year 71·1% vs 62·9%), but grade ≥3 (87% vs 76%) and fatal adverse events (6% vs 4%) were higher.
RCTn = 899
Lenz et al. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial